Global med tech company Terumo BCT announced that its Spectra Optia Apheresis System has received regulatory approvals for new therapeutic indications in 14 countries across the Latin America region.
The newly approved treatment indications include sickle cell disease (SCD), Guillain-Barré syndrome (GBS) and myasthenia gravis (MG). The new indications open new clinical possibilities for underdiagnosed and underserved patient populations in Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru and Uruguay.
Terumo’s Spectra technology is a therapeutic apheresis, cell processing, and cell collection platform that uses continuous-flow centrifugation and optical detection technology, providing operators the ability to perform a wide variety of apheresis procedures on a single platform.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!